Sionna Therapeutics Inc., a biopharmaceutical company focused on advancing treatments for cystic fibrosis, announced positive results from Phase 1 clinical trials for its NBD1 stabilizers, SION-719 and SION-451. These trials, conducted in healthy volunteers, demonstrated that both stabilizers were generally well tolerated and achieved desired pharmacokinetic targets, supporting their potential as add-ons to current standard care or in combination with other modulators. Sionna plans to progress SION-719 into a Phase 2a proof-of-concept trial for cystic fibrosis patients and SION-451 into a Phase 1 dual combination trial, both set to commence in the latter half of 2025. The company aims to release topline data from these trials by mid-2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.